Reforms help biotech firms secure funding with early human data.
Users are excited about the FDA pilot to speed up Phase I clinical trials, viewing the streamlining effort as amazing progress for US biomedical research.
No Digg Deeper questions have been answered for this story yet.
Unless the US reforms its drug development ecosystem, it risks surrendering leadership. Other nations have no intrinsic scientific edge, nor will they fully replicate the US network of VC, start-ups, and academic research that fuels our discovery engine.
https://www.statnews.com/2026/06/22/fda-speed-up-early-stage-single-study-clinical-trials/
... the initiative comes on the same day China approved the first CAR-T therapy for solid tumors. CAR-T has transformed blood cancers, but solid tumors have been a harder frontier. The technology was invented in the US, now China has an edge. h/t @BLLPHD https://www.prnewswire.com/news-releases/carsgen-announces-approval-of-satri-cel-the-worlds-first-car-t-cell-therapy-product-for-solid-tumors-302806312.html
... China often takes a brute force approach to drug development. America’s strength lies in its technological edge. Protecting the intellectual space around biomedical invention isn’t merely a commercial or legal chore; it preserves the engine that drives our public health...
@RuxandraTeslo This is amazing news!
@RuxandraTeslo @dylanmatt How does TGN1412 not get mentioned?
@RuxandraTeslo @dylanmatt LEGEND
@RuxandraTeslo Cutting six to twelve months sounds promising, but faster INDs won't fix funding instability. We need stability to keep trials here.